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ABSTRACT We previously showed that Entamoeba histolytica kills human cells
through a mechanism that we termed trogocytosis (“trogo-” means “nibble”),
due to its resemblance to trogocytosis in other organisms. In microbial eu-
karyotes like E. histolytica, trogocytosis is used to kill host cells. In multicellular
eukaryotes, trogocytosis is used for cell killing and cell-cell communication in a
variety of contexts. Thus, nibbling is an emerging theme in cell-cell interactions
both within and between species. When trogocytosis occurs between mamma-
lian immune cells, cell membrane proteins from the nibbled cell are acquired
and displayed by the recipient cell. In this study, we tested the hypothesis that
through trogocytosis, amoebae acquire and display human cell membrane pro-
teins. We demonstrate that E. histolytica acquires and displays human cell mem-
brane proteins through trogocytosis and that this leads to protection from lysis
by human serum. Protection from human serum occurs only after amoebae have
undergone trogocytosis of live cells but not phagocytosis of dead cells. Likewise,
mutant amoebae defective in phagocytosis, but unaltered in their capacity to
perform trogocytosis, are protected from human serum. Our studies are the first
to reveal that amoebae can display human cell membrane proteins and suggest
that the acquisition and display of membrane proteins is a general feature of
trogocytosis. These studies have major implications for interactions between E.
histolytica and the immune system and also reveal a novel strategy for immune
evasion by a pathogen. Since other microbial eukaryotes use trogocytosis for cell
killing, our findings may apply to the pathogenesis of other infections.
IMPORTANCE Entamoeba histolytica causes amoebiasis, a potentially fatal diarrheal
disease. Abscesses in organs such as the liver can occur when amoebae are able to
breach the intestinal wall and travel through the bloodstream to other areas of the
body. Therefore, understanding how E. histolytica evades immune detection is of
great interest. Here, we demonstrate for the first time that E. histolytica acquires and
displays human cell membrane proteins by taking “bites” of human cell material in a
process named trogocytosis (“trogo-” means “nibble”), and that this allows amoebae
to survive in human serum. Display of acquired proteins through trogocytosis has
been previously characterized only in mammalian immune cells. Our study suggests
that this is a more general feature of trogocytosis not restricted to immune cells and
broadens our knowledge of eukaryotic biology. These findings also reveal a novel
strategy for immune evasion by a pathogen and may apply to the pathogenesis of
other infections.
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Entamoeba histolytica is the protozoan parasite responsible for amoebiasis, a poten-tially fatal diarrheal disease. Amoebiasis is most prevalent in developing countries
in areas with poor sanitation (1–3). A recent study found that nearly 80% of infants
living in an urban slum in Bangladesh had been infected with E. histolytica by 2 years
of age (4). The infection has a wide range of clinical symptoms that include asymp-
tomatic infection, diarrhea, bloody diarrhea, and fatal abscesses outside of the intestine.
Bloody diarrhea arises when amoebic trophozoites (amoebae) invade and ulcerate the
intestine. Amoebae that have invaded the intestine can disseminate and cause ab-
scesses in other tissues, most commonly in the liver. Although amoebic liver abscesses
are rare, they are fatal if untreated. Little is known about the mechanisms that allow E.
histolytica to evade immune detection and disseminate upon entering the blood-
stream.
The parasite was named “histolytica” for its ability to damage tissue (“histo-” means
“tissue”; “lytic” means “dissolving”) (5–7). Despite this name-giving property, precisely
how amoebae invade and damage tissues is not clear. The most well-known virulence
factor is the amoeba surface D-galactose and N-acetyl-D-galactosamine (Gal/GalNAc)
lectin (8, 9), which mediates attachment to human cells and intestinal mucin (10–13).
Surface-localized and secreted cysteine proteases contribute to proteolysis of sub-
strates, including mucin and extracellular matrix (10–13). The profound cell killing
activity of amoebae is likely to drive tissue damage. Amoebae can kill almost any type
of human cell within minutes. Direct contact with human cells is required for killing to
occur (8, 9). Until recently, the accepted model was that the pore-forming amoebapores
act as secreted toxins (14–17). However, the contact dependence of cell killing (8, 9) and
the lack of killing activity in cell lysates and supernatants (6, 7, 18) are not consistent
with the presence of secreted toxins. Furthermore, transfer of amoebapores to human
cells has not been demonstrated.
We previously established a new paradigm by showing that E. histolytica kills human
cells through a mechanism that we termed trogocytosis (“trogo-” means “nibble”), due
to its resemblance to trogocytosis in other organisms (19). During trogocytosis, amoe-
bae kill human cells by extracting and ingesting “bites” of human cell membrane and
intracellular contents (19). We defined that trogocytosis requires amoebic actin rear-
rangements (19). It also requires signaling initiated by the Gal/GalNAc lectin, phospha-
tidylinositol 3-kinase (PI3K) signaling, and an E. histolytica C2 domain-containing kinase
(EhC2PK) (19). By applying multiphoton imaging using explanted mouse intestinal
tissue from fluorescent-membrane mice, we found that trogocytosis was required for
tissue invasion, demonstrating relevance to pathogenesis (19).
Trogocytosis is not unique to E. histolytica, as it can be observed in other eukaryotes
(20). Examples in microbes include reports of trogocytosis by Naegleria fowleri (21) and
Dictyostelium caveatum (22). In multicellular eukaryotes, trogocytosis is used for a
variety of cell-cell interactions in the immune system (23, 24), in the central nervous
system (25, 26), and during development (27). It is not yet clear how trogocytosis can
paradoxically be both a benign form of cell-cell interaction and a mechanism for cell
killing. The previous paradigm was that microbes engage trogocytosis for cell killing,
and trogocytosis in multicellular organisms was believed to be a benign form of cell-cell
interaction. However, recent reports have now shown that neutrophils can use trogo-
cytosis to kill parasites (28) and that neutrophils and macrophages can use trogocytosis
to kill cancer cells in a form of antibody-dependent cell-mediated cytotoxicity (29, 30).
Trogocytosis is therefore likely to be a conserved, fundamental form of eukaryotic
cell-cell interaction that can be cytotoxic or benign, depending on the context.
One intriguing outcome of trogocytosis between mammalian immune cells is that
it changes the makeup of cell surface proteins on both the donor and the recipient cell.
The nibbling cell displays the acquired membrane proteins from the nibbled cell on its
own surface (24, 31). Acquired membrane proteins appear as foci or patches on the
recipient cell. This allows the recipient cell to take on new properties that impact its
subsequent interactions with other cells (24, 31). For instance, uninfected dendritic cells
can acquire and display preloaded major histocompatibility complex class II (MHC II)
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molecules by nibbling infected dendritic cells, and thus they can present peptides from
microbes that they have not directly encountered, which has been termed “cross-
dressing” (24). Transferred molecules are not limited to MHC complexes, as induced
regulatory T cells can acquire cluster of differentiation (CD) molecules from mature
dendritic cells, including CD80 and CD86 cells (32). It has also been shown that
monocytes, NK cells, and granulocytes can acquire CD22, CD19, CD21, and CD79b from
antibody-opsonized B cells (33). In addition to allowing the nibbling cell to display
newly acquired membrane proteins, since membrane fragments are removed from the
nibbled cell, trogocytosis also affects the nibbled cell by effectively downregulating
surface proteins (34).
Since mammalian immune cells acquire and display membrane proteins through
trogocytosis, we hypothesized that amoebae may acquire and display human cell
membrane proteins. Amoebic display of human proteins would have significant impli-
cations for host-pathogen interactions. We predicted that one outcome of amoebic
human cell protein display might be the inhibition of lysis by human complement.
Previous studies have suggested that amoebae become more resistant to complement
after interacting with host cells or tissues and that complement resistance appears to
involve proteins on the amoeba surface (35–37).
Here, we show that E. histolytica acquires and displays human cell membrane
proteins. Acquisition and display of human cell membrane proteins requires actin and
direct contact and is associated with subsequent protection from lysis by human serum.
Protection from human serum occurs after amoebae have undergone trogocytosis, but
not phagocytosis, suggesting that protection is not generally associated with ingestion.
Collectively, these findings support a new model in which amoebae acquire and display
human cell membrane proteins through trogocytosis, leading to protection from lysis
by human serum complement. These studies have major implications for interactions
between E. histolytica and the immune system.
(This article was submitted to an online preprint archive [38].)
RESULTS
Amoebae acquire and display human cell membrane proteins. We first asked
whether trogocytosis by E. histolytica could result in transfer of human cell membrane
proteins to the cell membrane of an amoeba. Human Jurkat T cells were surface
biotinylated and then coincubated with amoebae. After coincubation, cells were fixed
and labeled with fluorescently conjugated streptavidin (Fig. 1A). Since cells were not
permeabilized, this approach required human cell proteins to be surface exposed and
to retain correct orientation for recognition by streptavidin. After 5 min of coincubation,
patches of streptavidin-labeled human cell proteins were detected on the surfaces of
amoebae (Fig. 1B and C, arrows). As with immune cell “cross-dressing” (24), the
biotin-streptavidin label appeared as foci on the amoeba surface. To track an individual
human cell membrane protein, immunofluorescence was used to detect human major
histocompatibility complex class I (MHC I) molecules (Fig. 1D). Following coincubation,
cells were fixed without permeabilization, and MHC I molecules were detected using a
monoclonal antibody. Similar to the biotin-streptavidin labeling experiments, MHC I
molecules were detected in foci on the surfaces of amoebae after 5 min of coincubation
(Fig. 1E and F). Thus, human cell membrane proteins were acquired and displayed by
amoebae.
Acquisition and display of human cell membrane proteins require actin. Tro-
gocytosis by E. histolytica requires actin rearrangements and is inhibited by cytochalasin
D (19). Therefore, we asked whether acquisition of human cell membrane proteins
required actin. Imaging flow cytometry was used to quantify biotinylated human cell
membrane proteins on the amoeba surface. It was important to distinguish between
amoebae that displayed human cell membrane proteins and amoebae that were
attached to intact, extracellular human cells. While the latter amoebae might also
display human cell membrane proteins, we focused our analysis on images that lacked
extracellular human cells, as this allowed for the highest stringency in quantifying
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FIG 1 Following interaction with human cells, human cell membrane proteins are displayed by amoebae. (A)
Human cell membrane proteins were labeled with biotin prior to coincubation with CMFDA-labeled amoebae. Cells
were coincubated for 5 min and immediately fixed. Following fixation, samples were labeled with fluorescently
conjugated streptavidin and DAPI. (B) Representative images of amoebae incubated alone or coincubated with
biotinylated human cells. Amoebae are shown in green, and streptavidin is shown in red. Nuclei are shown in blue.
Arrow indicates a patch of biotin-streptavidin localized to the amoeba surface. (C) Three-dimensional rendering of
Z stack images taken from panel B. The arrow indicates transferred biotin. (D) Human cells were labeled with
CellTracker deep red (CTDR) prior to coincubation with CMFDA-labeled amoebae. Cells were coincubated for 5 min
and immediately fixed. Following fixation, samples were labeled with DAPI and MHC I molecules were detected
using immunofluorescence. (E) Representative images of amoebae incubated alone or coincubated with CTDR-
labeled human cells. Amoebae are shown in green, human cell cytoplasm is shown in red, MHC I molecules are
shown in white, and nuclei are shown in blue. The arrow indicates a patch of MHC I molecules localized to the
amoeba surface. (F) Three-dimensional rendering of Z stack images taken from panel E. The arrow indicates
(Continued on next page)
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displayed human cell membrane proteins. Since human cell nuclei are not internalized
by amoebae during trogocytosis (19), human cell nuclei were fluorescently labeled, and
this was used to gate images that contained or lacked extracellular human cells.
Human cell nuclei were labeled with Hoechst dye, and human cell membrane
proteins were biotinylated prior to coincubation with amoebae. After gating of single
amoebae out of total cells (Fig. 2A; see also Fig. S1 in the supplemental material),
Hoechst staining was used to gate images of amoebae with and without extracellular
human cells (Fig. 2B, D, and F). Next, the extent of overlap of fluorescent streptavidin
and individual amoebae was quantified (Fig. 2C and E). In the dimethyl sulfoxide
(DMSO)-treated control amoebae, 25% of amoebae contained foci of biotin labeling,
while in the cytochalasin D-treated amoebae, 5% of amoebae contained foci of biotin
labeling (Fig. 2E). Thus, amoebae acquire and display human cell membrane proteins
through an actin-dependent process, consistent with trogocytosis. Moreover, only 3%
of biotin-positive amoebae had undergone phagocytosis (Fig. S2), consistent with a
predominant role for trogocytosis in the acquisition and display of human cell mem-
brane proteins.
Interaction with human cells leads to protection from lysis by human serum.
The acquisition and display of human cell membrane proteins has many potential
implications for host-parasite interactions. One possible implication is in resistance to
lysis by complement in human serum, particularly since it has been previously sug-
gested that ingestion of human erythrocytes protects amoebae from lysis by human
complement (35). Amoebae preferentially perform trogocytosis on live human cells
(19); therefore, amoebae were incubated in the presence or absence of live human cells
and then exposed to human serum (Fig. 3A; Fig. S3). Using imaging flow cytometry,
amoeba viability (Fig. 3C and D) and trogocytosis were simultaneously measured
(Fig. 3B; Fig. S4). Amoebae that had interacted with live human cells and had thus
undergone trogocytosis and acquired human cell membrane proteins were quantita-
tively protected from lysis by human serum (Fig. 3C and D; Fig. S5). Among amoebae
that had been incubated with human cells, amoebae that were lysed by human serum
had undergone quantitatively less trogocytosis than amoebae that survived exposure
to human serum (Fig. 3E to G). Therefore, trogocytosis is associated with subsequent
protection from lysis by human serum.
Protection from human serum lysis is dependent on contact with human cells.
We next asked if protection from serum lysis required direct contact between amoebae
and human cells in order to determine if protection is a consequence of trogocytosis
or if protection could be acquired through secreted human cell proteins or exosomes.
Amoebae and human cells were coincubated in transwell dishes, with or without direct
contact (Fig. 4A). Human cells were not able to pass through transwell membranes
(Fig. 4B). Protection from complement lysis occurred only when amoebae and human
cells were incubated together in the same chamber of the transwell, not when they
were separated (Fig. 4C). Protection from human serum thus required direct contact
between amoebae and human cells, supporting a requirement for trogocytosis in the
acquisition of protection.
Protection from human serum requires actin. Since acquisition and display of
human cell membrane proteins requires actin (Fig. 2), we next asked if treatment with
cytochalasin D would also abrogate protection from human serum. Amoebae were
treated with cytochalasin D, incubated in the presence or absence of human cells, and
then exposed to human serum. Imaging flow cytometry was used to simultaneously
measure trogocytosis (Fig. 5A) and amoeba viability (Fig. 5B). Amoebae that were
treated with cytochalasin D were impaired in their ability to undergo trogocytosis and
were not protected from serum lysis after coincubation with human cells. Since
FIG 1 Legend (Continued)
transferred MHC I. For panels B to F, images were collected from 4 independent experiments. For biotin
experiments, 76 images of amoebae with human cells and 21 images of amoebae alone were collected. For MHC
I experiments, 83 images of amoebae with human cells and 40 images of amoebae alone were collected.
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cytochalasin D inhibits cell motility, centrifugation was used to bring amoebae and
human cells into contact (Fig. S6). Under these conditions, cytochalasin D-treated
amoebae were still impaired in their ability to undergo trogocytosis and were not
protected from subsequent serum lysis. Thus, centrifugation does not rescue the defect
FIG 2 Acquisition of human cell membrane proteins is inhibited with cytochalasin D treatment. CMFDA-labeled amoebae were pretreated with
either cytochalasin D (Cyto. D) or DMSO (Control) and were then combined with Hoechst labeled human cells. Immediately after coincubation,
cells were placed on ice to halt ingestion and stained with fluorescently conjugated streptavidin. Samples were quantitatively analyzed using
imaging flow cytometry, with 10,000 images collected for each sample. (A) Gate used to identify single amoebae from total cells. Focused cells
were gated on single amoebae using the aspect ratio and intensity of CMFDA fluorescence. (B) Representative plots of images with and without
human cell nuclei (high- and low-Hoechst populations) are shown. The high-Hoechst population contained images of amoebae with human cells,
and the low-Hoechst population contained images of amoebae without human cells. (C) The overlap of biotin and CMFDA fluorescence was
measured, and biotin-positive images were gated. Representative plots of DMSO- and cytochalasin D-treated samples are shown. (D) Quantifi-
cation of plots from panel B. DMSO-treated samples are shown in blue, and cytochalasin D-treated samples are shown in orange. (E) Quantification
of plots from panel C. (F) Representative images of the populations shown in panel C. Amoebae are shown in green, cell nuclei are shown in blue,
and biotin is shown in magenta. Arrows indicate patches of transferred biotin. Whole human cells with stained nuclei are marked with asterisks.
Six replicates across 3 independent experiments were performed.
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in cytochalasin D-treated amoebae. Actin rearrangements are therefore required for
subsequent protection from lysis by human serum.
Protection occurs after trogocytosis and does not occur after phagocytosis. To
ask if protection from human serum specifically occurs after trogocytosis or if any form
of ingestion leads to protection from serum, we compared amoebae that had under-
FIG 3 Interaction with human cells leads to protection from lysis by human serum. (A) CMFDA-labeled amoebae were incubated alone or in the presence
of DiD-labeled human cells for 1 h. Cells were then exposed to either active human serum, heat-inactivated human serum, or M199s medium. Following
exposure to serum, samples were stained with Live/Dead violet, and viability was quantified using imaging flow cytometry, with 10,000 images collected
for each sample. (B) Representative plots showing internalization of human cells from amoebae incubated with human cells or in the absence of human
cells. (C) Representative plots comparing amoebic death from the conditions shown in panel B. (D) Quantification of amoebic death for all experimental
conditions. Cells exposed to M199s medium are shown in gray, to heat-inactivated (HI) human serum in red, and to active human serum in blue.
Percentages of dead amoebae were normalized to numbers of dead amoebae in the amoeba-alone samples that were treated with active human serum.
(E) Representative images of live and dead amoebae from amoebae coincubated with human cells and exposed to active human serum. Amoebae are
shown in green, human cell membranes in red, and dead cells in violet. (F) Representative histograms showing the mean fluorescence intensity (MFI)
of DiD in live and dead amoebae from samples exposed to human serum. (G) Quantification of the DID MFI shown in panel F. Ten replicates across 5
independent experiments were performed. ns, not significant.
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gone trogocytosis with those that had undergone phagocytosis. We previously showed
that amoebae undergo trogocytosis of live human cells and, in contrast, undergo
phagocytosis of prekilled human cells (19). Therefore, we asked if phagocytosis of
prekilled cells could also provide protection from complement lysis. Human cells were
prekilled by pretreating them with staurosporine to induce apoptosis (Fig. 6A). Amoe-
bae were coincubated with live or prekilled human cells or incubated in the absence of
human cells. Amoebae that had undergone trogocytosis or phagocytosis ingested
similar amounts of human cell material (Fig. 6B); however, amoebae were protected
from lysis only by human serum after undergoing trogocytosis (Fig. 6C). Therefore,
protection from lysis by human serum occurs specifically after trogocytosis of live cells.
To further distinguish between requirements for trogocytosis and phagocytosis, we
tested mutants deficient in E. histolytica rhomboid protease 1 (EhROM1) (EHI_197460),
a protease with roles in attachment and ingestion (39, 40). EhROM1 mutants have been
FIG 4 Protection from human serum lysis is dependent on contact with human cells. (A) Depiction of each transwell condition used in panels B to C.
CMFDA-labeled amoebae and DiD-labeled human cells were incubated alone, together, or separately under four different transwell conditions. Condition 1,
amoebae alone in the lower chamber; condition 2, amoebae and human cells together in the lower chamber; condition 3, human cells in the upper chamber
and amoebae in the lower chamber; and condition 4, amoebae and human cells together in the upper chamber and amoebae in the lower chamber. Cells were
coincubated in transwells for 1 h, and then cells from the lower chambers were harvested, exposed to human serum, and analyzed. Viability was assessed using
Live/Dead violet dye and imaging flow cytometry (B) Quantification of human-cell-positive amoebae under conditions 1 to 4 from panel A. (C) Quantification
of amoebic death under conditions 1 to 4. Percentages of dead amoebae were normalized to numbers of dead amoebae under condition 1 (amoebae alone).
Ten replicates across 5 independent experiments were performed.
FIG 5 Protection from human serum is actin dependent. CMFDA-labeled amoebae were incubated alone or in the
presence of DiD-labeled human cells for 1 h and then exposed to active human serum. Samples were then stained
with Live/Dead violet viability dye and analyzed by imaging flow cytometry. (A) Amoebae were either pretreated with
cytochalasin D (dark gray) or DMSO (light gray) for 1 h. The internalization of human cells was quantified. (B) The
quantification of amoebic death is shown. Percentages of dead amoebae were normalized to the numbers of dead
amoebae in the amoeba-alone DMSO-treated samples. Six replicates across 3 independent experiments were
performed.
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shown to be deficient in phagocytosis, pinocytosis, and attachment to live cells (39, 40).
Furthermore, silencing of EhROM1 does not change susceptibility to serum lysis,
making these mutants an ideal tool for testing the effects conferred by ingestion of
human cells (39, 40). We generated stable EhROM1 knockdown mutants (Fig. 7A), which
were deficient in attachment to healthy human cells (Fig. 7B and C), consistent with the
results of previous studies (40). Also consistently with previous studies, EhROM1 mutant
amoebae incubated alone were not more susceptible to serum lysis than control
amoebae (Fig. S7B). EhROM1 mutants did not exhibit a trogocytosis defect (Fig. 7D;
Fig. S8). As expected, EhROM1 mutants were defective in phagocytosis (Fig. 7E). After
trogocytosis, EhROM1 mutants were no more or less protected from lysis by human
serum than control amoebae (Fig. 7F; Fig. S7). Therefore, a mutant deficient in phago-
cytosis does not exhibit a difference in protection from serum, further supporting the
idea that phagocytosis is not involved in resistance to lysis by human serum. Moreover,
resistance to lysis by human serum is not associated with simple attachment to human
cells, since EhROM1 mutants are impaired in binding to live human cells but still exhibit
no difference in resistance to human serum. Together, these findings further under-
score the finding that protection from lysis by human serum is not associated with
phagocytosis.
Collectively, these results support a new model of immune evasion in which
amoebae perform trogocytosis on live human cells and through trogocytosis, acquire
and display human cell membrane proteins. Display of human cell membrane proteins
then leads to protection from human serum, most likely by inhibiting complement-
mediated lysis (Fig. 8).
DISCUSSION
Our studies revealed that amoebae acquire and display human cell membrane
proteins. This process is actin dependent and is associated with resistance to lysis by
human serum. Protection from lysis by human serum requires direct contact between
amoebae and human cells, is actin dependent, and is specifically associated with
trogocytosis, not phagocytosis. Collectively, these data suggest that amoebae acquire
and display human cell membrane proteins through trogocytosis and that this leads to
protection from lysis by human serum complement.
Complement resistance by amoebae is relevant to invasive disease. Once amoebae
have invaded intestinal tissue, they can spread from the intestine to the liver through
the portal vein (41), and they can ingest erythrocytes (42); thus, they are capable of
surviving in the bloodstream. A study that depleted complement by using cobra venom
factor in the hamster model of amoebic liver abscess found that loss of complement
FIG 6 Protection is associated with trogocytosis but not phagocytosis of human cells. (A) Human cells were pretreated with staurosporine (Stauro; dark gray)
or DMSO (light gray). The human cell viability before coincubation is shown. (B) Quantification of human cell internalization by amoebae. (C) Quantification of
amoebic death. Percentages of dead amoebae were normalized to the numbers of dead amoebae in the amoeba-alone samples. Eight replicates across 4
independent experiments were performed.
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was correlated with greater severity of liver lesions (43). Additionally, serum from
women was more effective in killing amoebae then serum from men, and men are
known to be more susceptible to invasive amoebiasis (44). Furthermore, pathogenic
amoebae have been shown to resist complement. E. histolytica appears to evade
complement deposition, while the closely related nonpathogenic species Entamoeba
dispar does not (45). Similarly, amoebae isolated from patients with invasive infection
resist complement, while strains isolated from asymptomatic patients are complement
sensitive (46).
Previous studies have hinted that amoebae become more resistant to complement
after interacting with host cells or tissues and that complement resistance involves
proteins on the amoeba surface. It has previously been demonstrated that amoebae
that were made resistant to complement lysis by hamster liver passage lost resistance
after treatment with trypsin (36), suggesting that complement resistance is associated
with proteins on the amoeba surface. It has also been shown that amoebae acquire
serum resistance after ingestion of live human erythrocytes and that resistant amoebae
stain positive with antiserum directed to erythrocyte membrane antigens (35). Though
this previous study described ingestion of erythrocytes as erythrophagocytosis, we now
know that amoebae are also capable of performing trogocytosis on live erythrocytes
FIG 7 EhROM1 knockdown mutants defective in phagocytosis but not trogocytosis are protected from serum lysis. Amoebae were stably transfected with an
EhROM1 knockdown plasmid (EhRom1) or a vector control plasmid (Control). (A) Silencing of EhROM1 was verified by using reverse transcriptase (RT) PCR. RT
was included () or omitted (–) as a control. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used to control for loading. (B) EhROM1 and vector
control transfectants were incubated on ice with live human cells for 1 h and then fixed and analyzed using confocal microscopy. The percentage of amoebae
with 3 or more attached human cells for each condition is displayed; a vector control is shown with open bars, and the EhROM1 knockdown mutant is shown
with blue bars. Four replicates across 2 independent experiments were performed. Twenty images were collected per slide, and 195 to 252 individual amoebae
were counted per condition. (C) Representative images from panel B. Amoebae are shown in green, and human cells are shown in red. The arrow indicates
an amoeba with a rosette of attached human cells. (D) CMFDA-labeled EhROM1 knockdown mutants (blue circles) or vector control transfectants (open circles)
were incubated alone or in the presence of live DiD-labeled human cells for 0, 5, 20, 40, or 80 min. Internalization of human cell material was quantified using
imaging flow cytometry. Twenty replicates across 10 independent experiments were performed. (E) CMFDA-labeled EhROM1 knockdown mutants (blue circles)
or vector control transfectants (open circles) were incubated alone or in the presence of heat-killed CTDR-labeled human cells for 0, 5, 20, 40, or 80 min.
Internalization of human cell material was quantified using imaging flow cytometry. Four replicates across 2 independent experiments were performed. (F)
EhROM1 (blue bar) or vector control (open bar) amoebae were coincubated with live human cells for 1 h and then exposed to human serum. Viability was
assessed using Live/Dead violet dye and imaging flow cytometry. Percent protection was calculated by subtracting the total lysis of amoebae coincubated with
human cells from the total lysis of amoebae incubated alone. Nine to 10 replicates across 5 independent experiments were performed. Protection data are
means of results from 2 replicates per experiment from all 5 experiments.
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(19). In older literature, amoebae were also seen to ingest bites of erythrocytes in a
process that was termed microphagocytosis (47). Therefore, we propose a model in
which invasive amoebae are able to evade complement detection in the blood by
undergoing trogocytosis of human cells and subsequently displaying human cell
membrane proteins.
Other mechanisms of complement resistance in E. histolytica, such as mimicry of the
complement regulatory protein CD59 (48, 49), an inhibitor of the membrane attack
complex (MAC), have been described. Amoebic cysteine proteinases play a role in
cleavage of complement components (50–52). Amoebae are also made temporarily
resistant to complement lysis through treatment with increasing doses of heat-
inactivated human serum, though the mechanism remains unclear (37, 53), and it was
recently found that amoebae do not develop resistance to serum from rats by this
method (54). As the percentage of amoebae lysed after exposure to human serum in
our assays never reached 100%, even under conditions where amoebae were incubated
alone, it is likely that multiple factors contribute to complement resistance in E.
histolytica, including display of human cell membrane proteins.
It will be of great interest to determine which human proteins are displayed by
amoebae. It is possible that complement regulatory proteins, such as CD55 and CD46,
are displayed by amoebae and that this directly promotes resistance to complement
lysis. Displayed human cell membrane proteins might also bind to soluble factors in
human serum, such as factor H. It is notable that acquired human cell membrane
proteins do not have an even distribution on the amoeba surface and instead appear
in foci. The staining pattern was similar for both biotin-streptavidin and MHC I staining.
In mammalian immune cells, similar focal localization of acquired membrane proteins
are seen with biotin-streptavidin staining, fluorescently tagged proteins, and immuno-
fluorescence (24, 55). It is not clear if the acquired membrane proteins are present in
lipid microdomains (e.g., lipid rafts). It is also possible that while patchy foci of acquired
membrane proteins are clearly seen, these proteins might also be found throughout
the membrane at concentrations below the limit of detection. In any case, the distri-
bution of human cell proteins appears sufficient to confer protection from comple-
ment.
We used EhROM1 knockdown mutants that were defective in phagocytosis but not
defective in trogocytosis to test whether protection was specifically associated with
trogocytosis. Consistent with the original description of EhROM1 mutants (40), we
FIG 8 Proposed model of protection from serum lysis. Amoebae encounter live human cells while invading the intestine or disseminating in the bloodstream
and perform trogocytosis. Trogocytosis leads to acquisition and display of human cell membrane proteins on the amoeba surface. One potential mechanism
for the acquisition and display of human cell membrane proteins is through fusion of the amoebic and human cell plasma membranes during trogocytosis
(during nibble). Human cell proteins might be directly transferred to the amoeba surface through membrane fusion at the site of trogocytosis without being
first internalized. Another potential mechanism is through internalization of bites during trogocytosis (after nibble). The ingested membrane proteins might
then be trafficked to the amoeba surface. Display of human cell membrane proteins then protects the amoebae from lysis in the blood by inhibiting the
complement cascade.
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found that they were still capable of attachment to human cells but were defective in
attaching to multiple human cells at the same time. Amoebae attached to numerous
human cells are termed “rosettes.” The phenotype of EhROM1 mutants is consistent
with the E. histolytica literature in general, where attachment phenotypes do not
manifest as abolishment of all attachment but instead result in decreased rosette
formation compared to that of control amoebae (8, 40, 56). Since most EhROM1
mutants still attached to at least one human cell, it appears that the lowered levels of
attachment were sufficient to allow trogocytosis to proceed and to allow acquisition of
human cell membrane proteins, since the mutants were still protected from lysis by
human serum.
With the discoveries of amoebic trogocytosis and display of human cell membrane
proteins, a new paradigm for amoeba-host interactions is emerging. We previously
showed that when amoebae kill cells, they do not ingest dead cell corpses (19). Prior
to this, amoebae were thought to fully ingest the corpses of the cells that they had
killed (5, 57, 58). Now, with the discovery of acquisition and display of human cell
membrane proteins, together with the lack of ingestion of cell corpses, a different
paradigm is emerging. It is possible that rather than acquiring nutrition by killing and
ingesting entire cells, amoebae nibble and acquire membrane proteins that contribute
to immune evasion. Invasive disease involves survival of amoebae in blood vessels.
Since trogocytosis contributes to tissue invasion (19), it is possible that amoebae
acquire human cell membrane proteins as they invade the intestine. Amoebae would
then be equipped to survive in the bloodstream and to spread to other tissues.
Moreover, since there is the potential for a variety of human cell proteins to be
displayed, display of human cell proteins may impact amoeba-host interactions in
many ways.
Display of human cell proteins acquired during trogocytosis is a novel strategy for
immune evasion by a pathogen. Since other microbial eukaryotes use trogocytosis for
cell killing, including Naegleria fowleri, there is the potential for display of acquired
membrane proteins to apply to the pathogenesis of other infections. Furthermore, our
studies extend acquisition and display of membrane proteins beyond mammalian
immune cells, suggesting that this may be a fundamental feature of eukaryotic trogo-
cytosis. How membrane proteins are acquired and displayed by immune cells during
trogocytosis is not well understood. Thus, ongoing studies of amoebae may shed light
on acquisition and display of membrane proteins during trogocytosis in general.
In summary, amoebae display human cell membrane proteins on their surfaces and
are protected from lysis by human serum after trogocytosis. We propose a new model
of immune evasion by E. histolytica whereby amoebae survive complement attack in
the bloodstream through trogocytosis and display of human cell membrane proteins.
This work broadens our understanding of trogocytosis as a conserved feature of
eukaryotic biology, as well as our understanding of the pathogenesis of amoebiasis.
MATERIALS AND METHODS
Cell culture. HM1:IMSS (ATCC) E. histolytica trophozoites (amoebae) were cultured at 35°C in TYI-S-33
medium supplemented with 80 U/ml penicillin, 80 g/ml streptomycin (Gibco), 2.3% Diamond vitamin
Tween 80 solution (40; Sigma-Aldrich), and 15% heat-inactivated adult bovine serum (Gemini Bio-
Products). Amoebae were harvested when tissue culture flasks reached 80 to 100% confluence and then
resuspended in M199s medium (Gibco medium M199 with Earle’s salts, L-glutamine, and 2.2 g/liter
sodium bicarbonate, without phenol red) supplemented with 5.7 mM L-cysteine, 25 mM HEPES, and 0.5%
bovine serum albumin.
Human Jurkat T cells from the ATCC (clone E6-1) were cultured at 37°C and 5% CO2 in RPMI 1640
medium (Gibco; RPMI 1640 with L-glutamine and without phenol red) supplemented with 10 mM HEPES,
100 U/ml penicillin, 100 g/ml streptomycin, and 10% heat-inactivated fetal bovine serum (Gibco).
Human cells were harvested when numbers reached between 5 105 and 2 106 cells/ml and were
resuspended in M199s medium.
Generation of EhROM1 mutants. The EhROM1 silencing construct, made from a pEhEx plasmid
backbone, was generated by Khalil et al. as described previously (59). The construct contained 132 bp of
the trigger gene, EHI_048600, fused to 525 bp of EhROM1 (EHI_197460) (AmoebaDB: https://amoebadb
.org/amoeba/app/record/gene/EHI_197460). Amoebae were transfected with 20 g of the EhROM1
silencing construct using Attractene transfection reagent (Qiagen). Transfectants were then main-
tained under selection with Geneticin at 6 g/ml. Clonal lines were generated by limiting dilution
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in a 96-well plate contained in a BD GasPak EZ pouch system (BD Biosciences), and silencing was
confirmed with reverse transcriptase (RT) PCR. An individual clonal line was used for all experiments.
A vector control line was generated by transfection with the pEhEx trigger construct backbone,
using the same approach.
Confocal immunofluorescence assays. In the biotin transfer experiments, human cells were re-
suspended in 1 Dulbecco’s phosphate-buffered saline (PBS; Sigma-Aldrich) and then biotinylated
with EZ-Link sulfo-NHS-SS-biotin (sulfosuccinimidyl-2-[biotinamido]ethyl-1,3-dithiopropionate) (Thermo
Fisher Scientific) at 480 g/ml in 1 PBS for 25 min at 4°C. One molar Tris-HCl (pH 8) was added to the
samples for a final concentration of 100 mM to quench the reaction. Cells were next washed in 1 PBS
containing Tris-HCl (pH 8) at 100 mM and then resuspended in M199s. Amoebae were washed and
labeled in M199s with CellTracker green 5-chloromethylfluorescein diacetate (CMFDA; Invitrogen) at
310 ng/ml for 10 min at 35°C. Amoebae and human cells were combined at a 1:5 ratio in M199s and
coincubated for 5 min at 35°C. Following coincubation, cells were fixed with 4% paraformaldehyde
(Electron Microscopy Sciences) for 30 min at room temperature and stained with an Alexa Fluor 633
streptavidin conjugate (Invitrogen) at 20 g/ml for 1 h at 4°C. After fixation, samples were stained with
DAPI (4=,6-diamidino-2-phenylindole; Sigma-Aldrich) for 10 min at room temperature. Samples were then
incubated on coverslips precoated with collagen (collagen I, rat tail; Gibco), according to the manufac-
turer’s instructions, for 1 h at room temperature and mounted on glass slides using Vectashield (Vector
Laboratories). In some experiments, samples were incubated on Superfrost Plus microslides (VWR) for 1 h,
and coverslips were then mounted with Vectashield. Samples were imaged on an Olympus FV1000 laser
point-scanning confocal microscope or on an Intelligent Imaging Innovations hybrid spinning-disk
confocal microscope. Images, including 76 images of amoebae with human cells and 21 images of
amoebae alone, were collected from 4 independent experiments.
For the MHC class I immunofluorescence experiments, human cells and amoebae were separately
washed and resuspended in M199s. Amoebae and human cells were then combined at a 1:5 ratio in
M199s and coincubated for 5 min at 35°C. Following coincubation and fixation with 4% paraformalde-
hyde, samples were blocked for 1 h in PBS-T (0.1% Tween 20 in 1 PBS) supplemented with 20% goat
serum (Jackson Immunoresearch Labs Inc.) and 5% bovine serum albumin. Samples were then washed
in PBS-T and incubated overnight with an MHC class I monoclonal primary antibody (Thermo Fisher
Scientific HLA-ABC monoclonal antibody W6/32) at 10 g/l, followed by washing with PBS-T and
incubation with an anti-mouse Cy3 secondary antibody (Jackson Immunoresearch Laboratories Inc.) at
3.5 ng/ml at room temperature for 1 h. Samples were stained with DAPI and mounted on glass slides as
described above. Images, including 83 images of amoebae with human cells and 40 images of amoebae
alone, were collected from 4 independent experiments.
Imaging flow cytometry immunofluorescence assays. Amoebae were resuspended in M199s
media and pretreated with cytochalasin D (Sigma-Aldrich) at 20 M or with the equivalent volume of
dimethyl sulfoxide (DMSO) for 1 h at 35°C. Cytochalasin D and DMSO were kept in the media for the
duration of the experiment. Following pretreatment, amoebae were labeled with CellTracker green
CMFDA at 93 ng/ml for 10 min at 35°C. Human cells were labeled in culture with Hoechst 33342 dye
(Invitrogen) at 5 g/ml for 1 h at 37°C and then resuspended in 1 PBS. Human cells were then
biotinylated with EZ-Link sulfo-NHS-SS-biotin at 480 g/ml in 1 PBS for 25 min at 4°C. One hundred
millimolar Tris-HCl (pH 8) was used to quench the reaction, cells were washed in 100 mM Tris-HCl (pH 8)
and were resuspended in M199s. Amoebae and human cells were combined at a 1:5 ratio in M199s and
coincubated for 5 min at 35°C. After coincubation, samples were immediately placed on ice to halt
ingestion, stained with an Alexa Fluor 633 streptavidin conjugate at 20 g/ml for 1 h at 4°C, and fixed
with 4% paraformaldehyde for 30 min at room temperature. Fixed samples were resuspended in 1 PBS
and run on an Amnis ImageStreamX Mark II. Ten thousand events per sample were collected from six
repeats across three independent experiments.
Serum lysis assays. Amoebae were washed and labeled in M199s with CellTracker green CMFDA at
93 ng/ml for 10 min at 35°C. Human cells were washed and labeled in M199s with Diic18(5)-Ds
(1,1-dioctadecyl-3,3,3,3-tetramethylindodicarbocyanine-5,5-disulfonic acid [DiD]; Assay Biotech) at
21 g/ml for 5 min at 37°C and 10 min at 4°C. After being washed with M199s, amoebae and human cells
were combined at a 1:5 ratio in M199s and coincubated for 1 h at 35°C or amoebae were incubated under
the same conditions in the absence of human cells. Next, cells were pelleted at 400 g for 8 min
and were resuspended in 100% normal human serum (pooled normal human complement serum;
Innovative Research Inc.), heat-inactivated human serum (inactivated at 56°C for 30 min), or M199s.
Serum/medium was supplemented with 150 M CaCl2 and 150 M MgCl2 (see Fig. S2 in the
supplemental material). Next, cells were incubated for 30 min at 35°C. Cells were then washed and
resuspended in M199s media and incubated with Live/Dead fixable violet dead cell stain (Invitrogen)
that was prepared according to the manufacturer’s instructions at 4 l/ml for 30 min on ice. Next,
samples were fixed with 4% paraformaldehyde for 30 min at room temperature. Fixed samples were
pelleted and resuspended in 1 PBS and then run on an Amnis ImageStreamX Mark II. Ten thousand
events per sample were collected.
In the cytochalasin D experiments, amoebae were pretreated with cytochalasin D at 20 M or with
an equivalent volume of DMSO for 1 h at 35°C. Cytochalasin D/DMSO was kept in the media for the
duration of the experiment. In experiments where amoebae ingested live or prekilled cells, human cells
were pretreated in culture with staurosporine (Sigma-Aldrich) at 1 M or with the equivalent volume of
DMSO overnight at 37°C. Human cells were then washed and suspended in M199s media and labeled
with CellTracker deep red (CTDR) (Invitrogen) at 1 M for 30 min at 37°C. In transwell assays, amoebae
and human cells were incubated together at a 1:5 ratio or separately in 12-mm transwells with
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3.0-m-pore-size, 10-m-thick polycarbonate membrane inserts (Corning). In experiments using Eh-
ROM1 knockdown, stably transfected EhROM1 clonal mutants were compared to mutants that contained
a pEhEx trigger backbone vector control construct.
Ingestion assays. In trogocytosis assays, CMFDA-labeled transfectants were incubated alone or in
the presence of live DiD-labeled Jurkat cells for 0, 5, 20, 40, or 80 min. Samples were then labeled with
Live/Dead violet and fixed with 4% paraformaldehyde. Internalization of human cell material was
quantified using imaging flow cytometry. In phagocytosis assays, human cells were heat killed at 60°C for
40 min and were labeled with CTDR and Hoechst dyes prior to incubation with CMFDA-labeled amoebae.
Attachment assay. CMFDA-labeled amoebae were combined with CTDR-labeled live human cells at
a 1:5 ratio, centrifuged at 150 g for 5 min 4°C, and incubated on ice for 1 h. Samples were then fixed
with 4% paraformaldehyde. Samples were incubated on Superfrost Plus microslides (VWR) for 1 h,
coverslips were mounted with Vectashield, and slides were imaged on an Intelligent Imaging Innovations
hybrid spinning-disk confocal microscope. Twenty images were collected per slide. Amoebae with 3 or
more attached human cells were scored as attachment positive. Image collection and scoring were
performed in a blind manner.
Imaging flow cytometry analysis. Samples were run on an Amnis ImageStreamX Mark II, and 10,000
events were collected per sample. Data were analyzed using Amnis IDEAS software. Samples were gated
on focused cells, single amoebae, amoebae that had come in contact with human cells, and amoebae
that had internalized human material. From the single amoeba gate, amoebic death was quantified by
plotting the intensity of Live/Dead violet against side scatter and gating on Live/Dead violet-positive cells
(Fig. S3).
In the biotin transfer experiment, single amoebae were divided into high-Hoechst and low-Hoechst
populations in order to isolate single amoebae with and without human cells. Overlap of biotin with
CMFDA-labeled amoebae was plotted, and biotin-positive cells were selected from both high-Hoechst
and low-Hoechst populations (Fig. S1).
For calculation of the background level of phagocytosis, the imaging flow cytometry data from the
experiments shown in Fig. 2 were used. The DMSO control-treated amoebae were used for this analysis.
Single amoebae were gated from total cells. Next, biotin-positive amoebae were gated. Amoebae
associated with human cell nuclei that were surrounded by a biotin-streptavidin ring were considered
phagocytosis negative, while amoebae associated with human cell nuclei that lacked a biotin ring were
considered phagocytosis positive. Amoebae that were not associated with human cell nuclei were
considered phagocytosis negative. Some amoebae were out of focus or were associated with too many
human cells to reliably score; thus, these images were left unscored. The first 100 images in the
biotin-positive amoeba gate that could be scored (300 total images from three independent experi-
ments) were analyzed. Since some images were unscored, more than 100 total images were analyzed per
experiment, as indicated in the raw-data table. Images were counted independently by two different
researchers, and the counts were averaged.
In the trogocytosis and phagocytosis assays, focused cells were gated from total collected events.
Next, single cells were gated, and then single amoebae were gated. Amoebae positive for human cells
were gated, and internalization of human cells was measured (Fig. S5).
Statistical analysis. All statistical analyses were performed using GraphPad Prism. All data plots
display means and standard deviation values. Data were statistically analyzed using Student’s unpaired
t test (no significant difference was indicated by a P of 0.05; *, P 0.05; **, P 0.01; ***, P 0.001; ****,
P 0.0001).
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